Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: Clinical findings

E. Jonasch, C. Wood, P. Tamboli, L. C. Pagliaro, S. M. Tu, J. Kim, P. Srivastava, C. Perez, L. Isakov, N. Tannir

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4 weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10. Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of 11 × 106 U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2 came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen.

Original languageEnglish (US)
Pages (from-to)1336-1341
Number of pages6
JournalBritish Journal of Cancer
Volume98
Issue number8
DOIs
StatePublished - Apr 22 2008
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Vaccination
Vaccines
Interleukin-2
Neoplasms
Nephrectomy
Injections
Therapeutics
Appointments and Schedules

Keywords

  • Autologous vaccine
  • Immunotherapy
  • Phase II study
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine : Clinical findings. / Jonasch, E.; Wood, C.; Tamboli, P.; Pagliaro, L. C.; Tu, S. M.; Kim, J.; Srivastava, P.; Perez, C.; Isakov, L.; Tannir, N.

In: British Journal of Cancer, Vol. 98, No. 8, 22.04.2008, p. 1336-1341.

Research output: Contribution to journalArticle

Jonasch, E, Wood, C, Tamboli, P, Pagliaro, LC, Tu, SM, Kim, J, Srivastava, P, Perez, C, Isakov, L & Tannir, N 2008, 'Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: Clinical findings', British Journal of Cancer, vol. 98, no. 8, pp. 1336-1341. https://doi.org/10.1038/sj.bjc.6604266
Jonasch, E. ; Wood, C. ; Tamboli, P. ; Pagliaro, L. C. ; Tu, S. M. ; Kim, J. ; Srivastava, P. ; Perez, C. ; Isakov, L. ; Tannir, N. / Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine : Clinical findings. In: British Journal of Cancer. 2008 ; Vol. 98, No. 8. pp. 1336-1341.
@article{ef359d1a3aff484e8c5e9b659e33a110,
title = "Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: Clinical findings",
abstract = "The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4 weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10. Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of 11 × 106 U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2 came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen.",
keywords = "Autologous vaccine, Immunotherapy, Phase II study, Renal cell carcinoma",
author = "E. Jonasch and C. Wood and P. Tamboli and Pagliaro, {L. C.} and Tu, {S. M.} and J. Kim and P. Srivastava and C. Perez and L. Isakov and N. Tannir",
year = "2008",
month = "4",
day = "22",
doi = "10.1038/sj.bjc.6604266",
language = "English (US)",
volume = "98",
pages = "1336--1341",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine

T2 - Clinical findings

AU - Jonasch, E.

AU - Wood, C.

AU - Tamboli, P.

AU - Pagliaro, L. C.

AU - Tu, S. M.

AU - Kim, J.

AU - Srivastava, P.

AU - Perez, C.

AU - Isakov, L.

AU - Tannir, N.

PY - 2008/4/22

Y1 - 2008/4/22

N2 - The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4 weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10. Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of 11 × 106 U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2 came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen.

AB - The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4 weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10. Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of 11 × 106 U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2 came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen.

KW - Autologous vaccine

KW - Immunotherapy

KW - Phase II study

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=42149092508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149092508&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604266

DO - 10.1038/sj.bjc.6604266

M3 - Article

C2 - 18362942

AN - SCOPUS:42149092508

VL - 98

SP - 1336

EP - 1341

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -